Avascular Necrosis

Back

Practice Essentials

Avascular necrosis (AVN) is defined as cellular death of bone components due to interruption of the blood supply; the bone structures then collapse, resulting in pain, loss of joint function and long-term joint damage.

AVN usually involves the epiphysis (end part of a long bone), such as the femoral and humeral heads and the femoral condyles, but small bones can also be affected. In clinical practice, AVN is most commonly encountered in the hip.[1, 2] Most available data regarding the natural history, pathology, pathogenesis, and treatment of AVN pertains to femoral head necrosis.

AVN is associated with numerous conditions. Patients taking corticosteroids and organ transplant recipients are particularly at risk of developing AVN. AVN of the jaw has been described in patients taking bisphosphonates and, more recently, denosumab.[3, 4] For full discussion of this entity, see Bisphosphonate-Related Osteonecrosis of the Jaw.

For diagnosis, plain radiography is the most appropriate initial imaging study, although findings are unremarkable in the early stages of AVN.MRI is the most sensitive and specific imaging modality. See Workup.

Early diagnosis and appropriate intervention can delay the need for joint replacement. However, most patients present late in the disease course. Without treatment, the process is almost always progressive, leading to joint destruction within 5 years. See Treatment.

Pathophysiology

Although the pathophysiology of AVN is not fully understood, the final common pathway is interruption of blood flow to the bone. AVN often affects bones with a single terminal blood supply, such as the femoral head, carpals, talus, and humerus. The earliest pathologic characteristics of osteonecrosis are necrosis of hematopoietic cells and adipocytes followed by interstitial marrow edema[5] .

Osteocyte necrosis occurs after approximately 3 hours of anoxia, but histological signs of osteocyte death do not appear until approximately 24 to 72 hours after oxygen deprivation[5] . Interruption of the vascular supply and resultant necrosis of marrow, medullary bone, and cortex are theorized to be caused by the mechanisms listed below. However, individual patients usually have more than one risk factor; this indicates that the pathogenesis of AVN is likely multifactorial.

Epidemiology

Frequency

United States

The frequency of AVN depends on the site involved. The most common site is the hip; other locations include the carpals, talus, femur, metatarsal, mandible, and humerus. In the United States, approximately 15,000 new cases of AVN are reported each year. AVN accounts for more than 10% of total hip replacement surgeries performed in the United States. Osteonecrosis of the jaw associated with bisphosphonate has also been well studied and reported. Most patients with osteonecrosis of the jaw also had an ongoing malignancy and/or had undergone a recent dental procedure.[8, 3, 9]

International

In most countries, the incidence and prevalence of AVN are not well reported. A Japanese survey estimated that 2500-3300 cases of AVN of the hip occur each year; of these, 34.7% were due to corticosteroid use, 21.8% to alcohol abuse, and 37.1% to idiopathic mechanisms.[10]

Mortality/morbidity

Data on mortality rates associated with AVN are not available. Most data involve AVN of the hip. Mortality rates are low and vary based on the operative procedure used to treat AVN.

Morbidity rates are high and depend on the underlying cause. Morbidity rates associated with AVN of the hip are high; the prevalence of long-term disability is significant. Despite advances in orthopedic procedures, most patients with advanced AVN require more than one hemiarthroplasty or total hip replacement during their lifetime.

In a study that included 1706 patients who underwent total hip replacement for AVN of the femoral head, Lovecchio et al concluded that AVN is an independent risk factor for transfusion up to 72 hours postoperatively and for readmission up to 30 days postoperatively. Bleeding requiring transfusion was the most common medical complication, occurring in 19.6% of patients with AVN compared with 13.9% of those without AVN (P< 0.001).[11]

Race-, sex-, and age-related demographics

AVN has no racial predilection except for cases associated with sickle cell disease and hemoglobin S and SC disease, which predominantly occur in people of African and Mediterranean descent.

With the exception of AVN associated with systemic lupus erythematosus, AVN is more common in men, with an overall male-to-female ratio of 8:1.

AVN is a disease of middle age that most often occurs during the fourth or fifth decade of life and is bilateral in more than half of cases.

History

Avascular necrosis (AVN) may be asymptomatic and is occasionally discovered incidentally on radiographs. Symptoms depend on the affected joint. Medullary infarcts are usually silent, and infarcts of the small bones of the hands and feet are often symptomatic.

Pain in the affected joint is typically the presenting symptom of AVN, regardless of the location. Patients with AVN of the femoral head often report groin or anterior thigh pain that is exacerbated by weight bearing. The pain may initially be mild but progressively worsens over time and subsequently may be present at rest or at night.

Large infarcts, such as those due to Gaucher disease and hemoglobinopathies, are associated with very severe pain.

Causes

AVN may be primary or idiopathic. For AVN that is secondary or associated with an underlying condition or exposure, the following factors have been identified:

Physical Examination

Initially, the physical examination findings of AVN may be unrevealing. Abnormal physical findings depend on the location and severity of disease. With progression of AVN of the hip, joint function deteriorates and the patient may walk with a limp. AVN of smaller, non–weight-bearing joints typically does not cause significant disability. Findings may include the following:

Approach Considerations

No laboratory test findings specifically suggest or confirm the presence of avascular necrosis (AVN). Plain radiographic findings are unremarkable in early stages of AVN. Nevertheless, the American College of Radiology (ACR) considers x-ray of the pelvis and hips the most appropriate initial imaging study in patients at risk for AVN who present with hip pain.[18] If radiographs are normal or show femoral head lucencies suspicious for osteonecrosis, magnetic resonance imaging (MRI) of the hips without contrast is most appropriate.[18]

The ACR advises that MRI is the most sensitive and specific imaging modality for diagnosis and provides optimal evaluation of the likelihood of articular collapse. Involvement of greater than 30-50% of the femoral head, often in the sagittal plane, indicates significantly increased risk of articular collapse.[18]

Additional ACR recommendations include the following[18] :

For more information, see Imaging in Avascular Necrosis of the Femoral Head.

Histology is the criterion standard for diagnosis of AVN. However, bone biopsy is not routinely performed because of the availability of sensitive noninvasive tests such as MRI.

Histologic Findings

Histology is the criterion standard for diagnosis of AVN, although it is usually unnecessary. The histologic specimen is usually obtained during surgery, although it is occasionally obtained during diagnostic bone biopsy. Histologic changes are observed in both cortical bone and bone marrow.

In the early stage, interstitial edema and plasmostasis is confined to the bone marrow. As the severity progresses, osteocytes continue to disappear and necrotic tissue fills the medullary spaces. New living bone is laminated onto dead trabeculae with partial resorption of dead bone. In the subchondral trabeculae, bone resorption exceeds formation leading to the net removal of bone, loss of structural integrity of trabeculae, subchondral fracture, and joint incongruity[5] .

Staging

Several different staging systems have been developed and continue to be used. Ficat initially developed an AVN staging system based on radiologic findings. This staging system was revised after the widespread use of MRI in the workup of AVN. The staging system presented in the below table is based on the consensus of the Subcommittee of Nomenclature of the International Association on Bone Circulation and Bone Necrosis (ARCO: Association of Research Circulation Osseous). The most important consideration is collapse of the femoral head cortex. Repair and complete recovery may be possible prior to collapse. Afterward, the collapse is irreversible[19] .

Staging of Avascular Necrosis



View Table

See Table

 

Radiography

Plain radiographic findings are unremarkable in early stages of AVN. Nevertheless, the American College of Radiology considers x-ray of the pelvis the most appropriate initial imaging study in patients at risk for AVN who present with hip pain.Both an anteroposterior view of the pelvis and a frog-leg lateral view of the hip are necessary, as articular collapse or cortical depression may be seen on only one of those projections.[18]

In children, the earliest radiographic findings of AVN include the following[18] :

Subsequentl findings in pediatric patients include fragmentation, resorption, reossification, and remodeling of the femoral head and neck.[18]

In mild-to-moderate AVN, radiographs demonstrate sclerosis and changes in bone density. In advanced disease, bone deformities, such as flattening, subchondral radiolucent lines (crescent sign), and collapse of the femoral head, are evident (see images below).



View Image

Avascular necrosis in the femoral head resulting from corticosteroid therapy.



View Image

Avascular necrosis of the shoulder showing subchondral radiolucent lines (crescent sign).

Magnetic Resonance Imaging

MRI is the most sensitive and specific imaging procedure for AVN, of the hip with an overall sensitivity that exceeds 90%. The specificity of MRI is also very high. The use of gadolinium is particularly useful in early detection.

MRI findings of AVN include decreased signal intensity in the subchondral region on both T1- and T2-weighted images, suggesting edema (water signal) in early disease. This relatively nonspecific finding is often localized in the medial aspect of the femoral head. This abnormality is observed in 96% of cases.

The next stage is characterized by a reparative process (reactive zone) and shows low signal intensity on T1-weighted scans and high signal intensity on T2-weighted scans. This finding is diagnostic for AVN (see images below).



View Image

Avascular necrosis of both femoral heads. This T1-weighted image shows decreased signal intensity in both femoral heads.



View Image

MRI of the distal femur and proximal tibia. This T2-weighted image shows increased signal intensity in the marrow.

Advanced AVN is characterized by deformity of the articular surface and by calcification, which are also easily detected with radiography and CT scanning.

Radionuclide Bone Scan

In early AVN, osteoblastic activity and blood flow are increased; thus, the sensitivity of radionuclide bone scan is better than that of plain films at this stage.

The central area of decreased uptake is surrounded by an area of increased uptake. This phenomenon is known as the doughnut sign and indicates the reactive zone surrounding the necrotic area.

Limitations of bone scan include the following:

Computed Tomography

Computed tomography (CT) is not commonly used for assessment of osteonecrosis in pediatric patients. In adults, CT is used principally to provide information for surgical planning, by determining the severity and location of articular collapse and providing evidence of early secondary degenerative joint disease.[18]

CT scans show sclerosis in the central part of femoral head as an asterisk sign. Changes in the anterior part of the femoral head are easily observed

Medical Care

Medical management of avascular necrosis (AVN) primarily depends on the location and severity of disease, as well as the patient's age and general health. Treatment outcomes correlate directly with the stage of the disease. No medical treatment has proven effective in preventing or arresting the disease process.

Conservative measures include limited weight bearing with crutches and pain medications. This may be beneficial and is a reasonable initial course of action if the involved segment is smaller than 15% and far from the weight-bearing region. Immobilization may be helpful in some cases (eg, AVN of the distal femur or tibia). In advanced AVN, the disease course is unaffected by activity and will eventually require surgery.

Treatment with bisphosphonates may be helpful. Although large-scale, randomized, double-blind studies have not been performed, a systematic review of eight articles involving 788 hips suggested that alendronate has short-term efficacy in reducing pain, improving articular function, slowing of bone collapse progression, and delaying the need for total hip arthroplasty in adults with AVN[20]

Iloprost, a vasoactive prostaglandin analog that is approved for inhalational treatment of pulmonary hypertension, has shown clinical and radiographic benefits in early-stage AVN when administered intravenously. Iloprost produces vasodilation and increases microcirculation, reducing bone marrow edema and relieving pain and other accompanying symptoms; it inhibits platelet aggregation and diminishes the concentration of oxygen free radicals and leukotrienes.[21, 22]

Statin therapy to prevent corticosteroid-induced AVN may be helpful. Pritchett reported a 1% incidence of AVN in 284 patients who were on statin therapy during the entire period of corticosteroid treatment (average, 7.5 y).[23] The use of high-dose corticosteroids carries a reported 3-20% incidence of AVN.

Extracorporeal shockwave therapy (ESWT) has shown beneficial effects in early AVN of the femoral head. ESWT may relieve pain and improve hip function of the hip, and induce regression of AVN.[24, 25] ESWT may be combined with alendronate therapy.[24]

 

Surgical Care

Several surgical procedures have been used in an attempt to treat AVN, with variable success. No surgical procedure is the consensual best among surgeons in the treatment of AVN. In early stages of AVN (precollapse), core decompression with or without bone graft is typically considered the most appropriate treatment. In late stages, characterized by collapse, femoral head deformity, and secondary osteoarthritis, total hip arthroplasty is the most appropriate treatment.

Core decompression

Researchers postulate that core decompression improves circulation by decreasing intramedullary pressure and preventing further ischemia and progressive joint destruction. The best results vary from 34-95%, which is significantly better than results of conservative treatment.[26] The best results are obtained when treating patients with early AVN (precollapse). Core decompression is also effective for pain control.

Bone graft

Bone graft options include structural cortical or medullary bone graft and vascularized bone graft with either a muscle-pedicle bone graft or free vascularized fibular graft.[27]

Bone grafting is combined with the following:

The best results have been reported with free vascularized bone grafts. Success rates of 70% and 91% have been reported in two small series.[28, 29]

Advantages of free vascularized grafts compared with total hip arthroplasty include the following:

Disadvantages of free vascularized grafts include the following:

In a review of bone grafting through a window at the femoral head-neck junction, Zuo et al found that factors predicting good clinical success were absence of femoral head collapse or degree of collapse < 2 mm (Association Research Circulation Osseous [ARCO] stage IIIa). Surgical failure rates were high in patients with femoral head collapse >2 mm (ARCO stage IIIb and IIIc) and in those with necrotic lesions involving the lateral pillar (L2 and L3 type). Finally, patients  40 years of age and older had a worse prognosis than those younger than 40.[30]

Osteotomy

Several osteotomy procedures have been tried with variable success.

Intertrochanteric osteotomies have been performed in patients with posttraumatic AVN.

Transtrochanteric rotational osteotomy involves rotation of the femoral head and neck on the longitudinal axis. The necrotic anterosuperior part of the femoral head becomes posterior, and the weight-bearing force is transmitted to what was previously the posterior articular surface, which is not involved in the ischemic process. In 1992, Sugano and colleagues reported excellent results in 56% of patients who underwent this procedure.[31] Transtrochanteric rotational osteotomy is technically demanding.

Total hip arthroplasty

Most patients with advanced disease (stage III and above) require total hip arthroplasty. Total hip arthroplasty provides excellent pain relief for many years, although most young patients require repeat surgery. With high failure rates (10-50% after 5 years), patients with AVN will probably need a second total hip arthroplasty during their lifetime.

Cheung et al reported excellent long-term survival of cementless total hip arthroplasty for managing AVN of the hip. In their review of 182 total hip arthroplasties, 117 of them for AVN, 19.1- year survival was 97.1% for AVN patients and 96.2% for non-AVN patients.[32]

Cell therapy

The use of stem cells implanted via core decompression has been studied for the treatment of early-stage (precollapse) AVN of the femoral head.[33, 34, 35]  For example, Pilge et al reported benefit with the application of autologous bone marrow concentrate, derived from iliac crest aspirates. In this study, compared with core decompression alone, the addition of bone marrow stem cells seemed to decrease pain and other joint symptoms, improve range of motion, and prevent collapse of the femoral head.[21]

Hernigou et al reported superior long-term outcome with core decompression plus bone marrow injection compared with decompression alone in the same patient. Their study included 125 consecutive patients (78 males and 47 females) with bilateral corticosteroid-induced AVN.[36]

All patients had AVN at the same stage in both sides (stage I or II); the hip with lower volume of osteonecrosis, as measured with MRI, was treated with core decompression, and the contralateral hip was treated with decompression and percutaneous injection of mesenchymal cells (MSCs) obtained from bone marrow concentration. The average total number of MSCs (counted as number of colony-forming units–fibroblast) in each injection was 90,000 ± 25,000 cells (range, 45,000 to 180,000 cells).[36]

On follow-up conducted an average 25 years after the first surgery (range 20 to 30 years), 35 hips (28%) treated with cell therapy had collapsed, compared with 90 (72%) treated with decompression only. Total hip arthroplasty had been performed in 30 hips (24%) in the cell therapy group, versus 95 (76%) in the decompression-only group (P <  0.0001).[36]

Houdek et al reported beneficial results from injecting the combination of bone marrow–derived mesenchymal stem cells and platelet-rich plasma into the femoral head after standard hip decompression in patients with corticosteroid-induced AVN. In their preliminary study of 35 hips in 22 patients, use of this technique improved pain and function, and more than 90% of femoral heads had not collapsed at a minimum of 2 years.[37]

Systematic reviews of studies with patient-reported outcomes have demonstrated clinical benefit with the use of stem cells for hip AVN, with a low rate of complications, but have highlighted the lack of standardization with this technique. Comparisons across studies have been complicated by differences in etiology and severity of AVN, cell sources and doses, adjuvant therapies used, and outcome assessment methodology.[34, 35, 38, 39]

Although the assumption is that the injected stem cells are taken up and differentiate into osteoblasts, Im points out that the survival of stem cells implanted into the hip has not been studied. In other organs, tracking studies have shown that injected or implanted stem cells usually exert paracrine effects and then largely die off. Measures to improve stem cell survival by enhancing the vascularity and osteogenic potential of the treatment site are currently under study, and include use of adipose stem cells and the addition of angiogenic factors, such as vascular endothelial growth factor (VEGF).[39]

Other sites

AVN of the femoral condyles (knees) may respond to more conservative intervention such as arthroscopic lavage and debridement. AVN of the femoral condyles has a better prognosis than hip AVN, although osteoarthritis eventually develops.

In a study of 25 patients with 29 shoulders treated with arthroplasty for humeral head AVN, Ristow et al reported that both total shoulder arthroplasty and hemiarthroplasty are safe and effective treatments, regardless of etiology and radiographic staging. At a mean follow-up of 3.9 years (range, 1-8.5 years), all patients who underwent operative intervention showed statistically significant improvement in measurements of functionality.[40]

 

 

Consultations

Obtain consultation with an orthopedic surgeon. Early intervention can save affected joints and obviate the need for joint replacement.

Activity

In early AVN, patients should use crutches or other supports to avoid weight bearing. In advanced AVN, the disease course is unaffected by activity; surgery is the only option.

Medication Summary

No pharmaceutical treatment has been proven to prevent progression of avascular necrosis (AVN). Analgesics are often used as needed for pain relief.

Deterrence/Prevention

The following precautions can be taken to minimize the risk of developing avascular necrosis (AVN) and to improve outcomes in these patients:

For patients undergoing pelvic radiotherapy, a variety of pharmacological interventions for preventing AVN have been studied, including supplemental calcium and/or vitamin D, bisphosphonates, selective estrogen receptor modulators, hormone replacement therapy (estrogen or testosterone), denosumab, and calcitonin. However, a Cochrane review concluded that the evidence relating to those interventions is of very low certainty.[41]

Complications

See the list below:

Prognosis

The prognosis of AVN depends on the disease stage at the time of diagnosis and the presence of any underlying conditions. More than 50% of patients with AVN require surgical treatment within 3 years of diagnosis. Half of patients with subchondral collapse of the femoral head develop AVN in the contralateral hip.[42]

Poor prognostic factors include the following:

Patient Education

See the list below:

What is avascular necrosis (AVN)?What is the pathophysiology of avascular necrosis (AVN)?What is the US prevalence of avascular necrosis (AVN)?What is the global prevalence of avascular necrosis (AVN)?What is the morbidity and mortality associated with avascular necrosis (AVN)?What are the racial predilections of avascular necrosis (AVN)?What are the sexual predilections of avascular necrosis (AVN)?Which age groups have the highest prevalence of avascular necrosis (AVN)?Which clinical history findings are characteristic of avascular necrosis (AVN)?What causes avascular necrosis (AVN)?Which physical findings are characteristic of avascular necrosis (AVN)?Which conditions are included in the differential diagnoses of avascular necrosis (AVN)?What are the differential diagnoses for Avascular Necrosis?How is avascular necrosis (AVN) diagnosed?Which histologic findings are characteristic of avascular necrosis (AVN)?How is avascular necrosis (AVN) staged?What is the role of radiography in the workup of avascular necrosis (AVN)?What is the role of MRI in the workup of avascular necrosis (AVN)?What is the role of bone scans in the workup of avascular necrosis (AVN)?What is the role of CT scans in the workup of avascular necrosis (AVN)?How is avascular necrosis (AVN) treated?What is the role of surgery in the treatment of avascular necrosis (AVN)?What is the role of core decompression in the treatment of avascular necrosis (AVN)?What is the role of bone graft in the treatment of avascular necrosis (AVN)?What is the role of osteotomy in the treatment of avascular necrosis (AVN)?What is the role of hip arthroplasty in the treatment of avascular necrosis (AVN)?What is the role of stem cell therapy in the treatment of avascular necrosis (AVN)?How is avascular necrosis (AVN) of the femoral condyles treated?How is humeral head avascular necrosis (AVN) treated?Which specialist consultations are beneficial to patients with avascular necrosis (AVN)?Which activity modifications are used in the treatment of avascular necrosis (AVN)?What is the role of medications in the treatment of avascular necrosis (AVN)?How is avascular necrosis (AVN) prevented?What are the possible complications of avascular necrosis (AVN)What is the prognosis of avascular necrosis (AVN)?What is included in patient education about avascular necrosis (AVN)?

Author

Sunny B Patel, MD, Chief Fellow, Department of Rheumatology, LSU Health Sciences Center

Disclosure: Nothing to disclose.

Coauthor(s)

Richa Dhawan, MD, CCD, Associate Professor, Director of Osteoporosis Clinic, Center of Excellence for Arthritis and Rheumatology, Louisiana State University Health Science Center at Shreveport

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Lawrence H Brent, MD, Associate Professor of Medicine, Sidney Kimmel Medical College of Thomas Jefferson University; Chair, Program Director, Department of Medicine, Division of Rheumatology, Albert Einstein Medical Center

Disclosure: Stock ownership for: Johnson & Johnson.

Chief Editor

Herbert S Diamond, MD, Visiting Professor of Medicine, Division of Rheumatology, State University of New York Downstate Medical Center; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital

Disclosure: Nothing to disclose.

Additional Contributors

Bryan L Martin, DO, Associate Dean for Graduate Medical Education, Designated Institutional Official, Associate Medical Director, Director, Allergy Immunology Program, Professor of Medicine and Pediatrics, Ohio State University College of Medicine

Disclosure: Nothing to disclose.

Jeanne K Tofferi, MD, MPH, FACP, Assistant Chief, Department of Rheumatology, Walter Reed Army Medical Center

Disclosure: Nothing to disclose.

Acknowledgements

William Gilliland, MD, MPHE, FACP, FACR Staff Rheumatologist, Walter Reed Army Medical Center; Professor of Medicine, Assistant Dean of Curriculum, Uniformed Services University of the Health Sciences

Disclosure: Nothing to disclose.

References

  1. Bose VC, Baruah BD. Resurfacing arthroplasty of the hip for avascular necrosis of the femoral head: a minimum follow-up of four years. J Bone Joint Surg Br. 2010 Jul. 92(7):922-8. [View Abstract]
  2. Steffen RT, Athanasou NA, Gill HS, Murray DW. Avascular necrosis associated with fracture of the femoral neck after hip resurfacing: histological assessment of femoral bone from retrieval specimens. J Bone Joint Surg Br. 2010 Jun. 92(6):787-93. [View Abstract]
  3. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006 May 16. 144(10):753-61. [View Abstract]
  4. Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014 Apr. 19(2):403-10. [View Abstract]
  5. Shah KN, Racine J, Jones LC, Aaron RK. Pathophysiology and Risk Factors for Osteonecrosis. Current Reviews in Musculoskeletal Medicine. Sept 2015. 8(3): 201–209:[View Abstract]
  6. Kawai K, Tamaki A, Hirohata K. Steroid-induced accumulation of lipid in the osteocytes of the rabbit femoral head. A histochemical and electron microscopic study. J Bone Joint Surg Am. 1985 Jun. 67(5):755-63. [View Abstract]
  7. Wang GJ, Sweet DE, Reger SI, et al. Fat-cell changes as a mechanism of avascular necrosis of the femoral head in cortisone-treated rabbits. J Bone Joint Surg Am. 1977 Sep. 59(6):729-35. [View Abstract]
  8. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005 Feb. 34(2):120-3. [View Abstract]
  9. Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2009 Mar. 36(3):478-90. [View Abstract]
  10. Ninomiya S. An epidemiological survey of idiopathic avascular necrosis of the femoral head in Japan. Annual Report of Japanese Investigation Committee for Intractable Disease. 1989.
  11. Chiu HY, Wang IT, Huang WF, Tsai YW, Shiu MN, Tsai TF. Increased risk of avascular necrosis in patients with psoriatic disease: A nationwide population-based matched cohort study. J Am Acad Dermatol. 2017 May. 76 (5):903-910.e1. [View Abstract]
  12. Aaron RK, Voisinet A, Racine J, Ali Y, Feller ER. Corticosteroid-associated avascular necrosis: dose relationships and early diagnosis. Ann N Y Acad Sci. 2011 Dec. 1240(1):38-46. [View Abstract]
  13. Lawson-Ayayi S, Bonnet F, Bernardin E, et al. Avascular necrosis in HIV-infected patients: a case-control study from the Aquitaine Cohort, 1997-2002, France. Clin Infect Dis. 2005 Apr 15. 40(8):1188-93. [View Abstract]
  14. Mehta P, Nelson M, Brand A, Boag F. Avascular necrosis in HIV. Rheumatol Int. 2013 Jan. 33(1):235-8. [View Abstract]
  15. Enright H, Haake R, Weisdorf D. Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation. Am J Med. 1990 Dec. 89(6):733-8. [View Abstract]
  16. Fink JC, Leisenring WM, Sullivan KM, et al. Avascular necrosis following bone marrow transplantation: a case-control study. Bone. 1998 Jan. 22(1):67-71. [View Abstract]
  17. Rolston VS, Patel AV, Learch TJ, Li D, Karayev D, Williams C, et al. Prevalence and Associations of Avascular Necrosis of the Hip in a Large Well-characterized Cohort of Patients With Inflammatory Bowel Disease. J Clin Rheumatol. 2018 May 24. [View Abstract]
  18. [Guideline] Murphey MD, Roberts CC, Bencardino JT, Appel M, Arnold E, Chang EY, et al. ACR Appropriateness Criteria Osteonecrosis of the Hip. J Am Coll Radiol. 2016 Feb. 13 (2):147-55. [View Abstract]
  19. Staging of Avascular Necrosis. www.OrthopaedicsOne.com. Available at http://www.orthopaedicsone.com/display/Main/Staging+of+Avascular+Necrosis. Feb 2009; Accessed: October 2, 2018.
  20. Luo RB, Lin T, Zhong HM, Yan SG, Wang JA. Evidence for using alendronate to treat adult avascular necrosis of the femoral head: a systematic review. Med Sci Monit. 2014 Nov 26. 20:2439-47. [View Abstract]
  21. Pilge H, Bittersohl B, Schneppendahl J, Hesper T, Zilkens C, Ruppert M, et al. Bone Marrow Aspirate Concentrate in Combination With Intravenous Iloprost Increases Bone Healing in Patients With Avascular Necrosis of the Femoral Head: A Matched Pair Analysis. Orthop Rev (Pavia). 2016 Nov 17. 8 (4):6902. [View Abstract]
  22. Claßen T, Becker A, Landgraeber S, Haversath M, Li X, Zilkens C, et al. Long-term Clinical Results after Iloprost Treatment for Bone Marrow Edema and Avascular Necrosis. Orthop Rev (Pavia). 2016 Mar 21. 8 (1):6150. [View Abstract]
  23. Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop. 2001 May. (386):173-8. [View Abstract]
  24. Wang CJ, Cheng JH, Huang CC, Yip HK, Russo S. Extracorporeal shockwave therapy for avascular necrosis of femoral head. Int J Surg. 2015 Dec. 24 (Pt B):184-7. [View Abstract]
  25. Gao F, Sun W, Li Z, Guo W, Wang W, Cheng L, et al. High-Energy Extracorporeal Shock Wave for Early Stage Osteonecrosis of the Femoral Head: A Single-Center Case Series. Evid Based Complement Alternat Med. 2015. 2015:468090. [View Abstract]
  26. Van Laere C, Mulier M, Simon JP, et al. Core decompression for avascular necrosis of the femoral head. Acta Orthop Belg. 1998 Sep. 64(3):269-72. [View Abstract]
  27. Aldridge JM 3rd, Urbaniak JR. Avascular necrosis of the femoral head: role of vascularized bone grafts. Orthop Clin North Am. 2007 Jan. 38(1):13-22, v. [View Abstract]
  28. Hasegawa Y, Iwata H, Torii S, et al. Vascularized pedicle bone-grafting for nontraumatic avascular necrosis of the femoral head. A 5- to 11-year follow-up. Arch Orthop Trauma Surg. 1997. 116(5):251-8. [View Abstract]
  29. Urbaniak JR, Coogan PG, Gunneson EB, et al. Treatment of osteonecrosis of the femoral head with free vascularized fibular grafting. A long-term follow-up study of one hundred and three hips. J Bone Joint Surg Am. 1995 May. 77(5):681-94. [View Abstract]
  30. Zuo W, Sun W, Zhao D, Gao F, Su Y, Li Z. Investigating Clinical Failure of Bone Grafting through a Window at the Femoral Head Neck Junction Surgery for the Treatment of Osteonecrosis of the Femoral Head. PLoS One. 2016. 11 (6):e0156903. [View Abstract]
  31. Sugano N, Takaoka K, Ohzono K, et al. Rotational osteotomy for non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Br. 1992 Sep. 74(5):734-9. [View Abstract]
  32. Cheung KW, Chiu KH, Chung KY. Long-term result of cementless femoral stem in avascular necrosis of the hip. Hip Int. 2014 Sep 1. [View Abstract]
  33. Gangji V, Hauzeur JP. Cellular-based therapy for osteonecrosis. Orthop Clin North Am. 2009 Apr. 40(2):213-21. [View Abstract]
  34. Lau RL, Perruccio AV, Evans HM, Mahomed SR, Mahomed NN, Gandhi R. Stem cell therapy for the treatment of early stage avascular necrosis of the femoral head: a systematic review. BMC Musculoskelet Disord. 2014 May 16. 15:156. [View Abstract]
  35. Hernigou P, Trousselier M, Roubineau F, Bouthors C, Chevallier N, Rouard H, et al. Stem Cell Therapy for the Treatment of Hip Osteonecrosis: A 30-Year Review of Progress. Clin Orthop Surg. 2016 Mar. 8 (1):1-8. [View Abstract]
  36. Hernigou P, Dubory A, Homma Y, Guissou I, Flouzat Lachaniette CH, Chevallier N, et al. Cell therapy versus simultaneous contralateral decompression in symptomatic corticosteroid osteonecrosis: a thirty year follow-up prospective randomized study of one hundred and twenty five adult patients. Int Orthop. 2018 May 9. [View Abstract]
  37. Houdek MT, Wyles CC, Collins MS, Howe BM, Terzic A, Behfar A, et al. Stem Cells Combined With Platelet-rich Plasma Effectively Treat Corticosteroid-induced Osteonecrosis of the Hip: A Prospective Study. Clin Orthop Relat Res. 2018 Feb. 476 (2):388-397. [View Abstract]
  38. Piuzzi NS, Chahla J, Schrock JB, LaPrade RF, Pascual-Garrido C, Mont MA, et al. Evidence for the Use of Cell-Based Therapy for the Treatment of Osteonecrosis of the Femoral Head: A Systematic Review of the Literature. J Arthroplasty. 2017 May. 32 (5):1698-1708. [View Abstract]
  39. Im GI. Stem Cell Therapy in Osteonecrosis of the Femoral Head. Hip Pelvis. 2018 Sep. 30 (3):135-137. [View Abstract]
  40. Ristow JJ, Ellison CM, Mickschl DJ, Berg KC, Haidet KC, Gray JR, et al. Outcomes of shoulder replacement in humeral head avascular necrosis. J Shoulder Elbow Surg. 2018 Sep 14. [View Abstract]
  41. van den Blink QU, Garcez K, Henson CC, Davidson SE, Higham CE. Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults. Cochrane Database Syst Rev. 2018 Apr 23. 4:CD010604. [View Abstract]
  42. Goker B, Block JA. Risk of contralateral avascular necrosis (AVN) after total hip arthroplasty (THA) for non-traumatic AVN. Rheumatol Int. 2006 Jan. 26(3):215-9. [View Abstract]
  43. Diz P, López-Cedrún JL, Arenaz J, Scully C. Denosumab-related osteonecrosis of the jaw. J Am Dent Assoc. 2012 Sep. 143(9):981-4. [View Abstract]
  44. Agarwala S, Jain D, Joshi VR, et al. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford). 2005 Mar. 44(3):352-9. [View Abstract]
  45. Lai KA, Shen WJ, Yang CY, et al. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am. 2005 Oct. 87(10):2155-9. [View Abstract]
  46. [Guideline] Aldridge JM 3rd, Urbaniak JR. Avascular necrosis of the femoral head: etiology, pathophysiology, classification, and current treatment guidelines. Am J Orthop. 2004 Jul. 33(7):327-32. [View Abstract]
  47. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009 May. 67(5 Suppl):61-70. [View Abstract]
  48. Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. 2009 May. 67(5 Suppl):75-84. [View Abstract]
  49. Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002 Oct. 32(2):94-124. [View Abstract]
  50. Bachiller FG, Caballer AP, Portal LF. Avascular necrosis of the femoral head after femoral neck fracture. Clin Orthop Relat Res. 2002 Jun. 87-109. [View Abstract]
  51. Bernasek TL, Stahl JL, Pupello D. Pyrolytic carbon endoprosthetic replacement for osteonecrosis and femoral fracture of the hip: a pilot study. Clin Orthop Relat Res. 2009 Jul. 467(7):1826-32. [View Abstract]
  52. Dodson TB. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009 May. 67(5 Suppl):44-52. [View Abstract]
  53. Dudkiewicz I, Covo A, Salai M, et al. Total hip arthroplasty after avascular necrosis of the femoral head: does etiology affect the results?. Arch Orthop Trauma Surg. 2004 Mar. 124(2):82-5. [View Abstract]
  54. Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009 May. 67(5 Suppl):96-106. [View Abstract]
  55. Gliklich R, Wilson J. Epidemiology of bisphosphonate-related osteonecrosis of the jaws: the utility of a national registry. J Oral Maxillofac Surg. 2009 May. 67(5 Suppl):71-4. [View Abstract]
  56. Hasse B, Ledergerber B, Egger M, Flepp M, Bachmann S, Bernasconi E, et al. Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: a nested case-control study. AIDS Res Hum Retroviruses. 2004 Sep. 20(9):909-15. [View Abstract]
  57. Jones LC, Hungerford MW, Khanuja HS, Hungerford DS. Outcome measures for evaluation of treatments for osteonecrosis. Orthop Clin North Am. 2009 Apr. 40(2):179-91. [View Abstract]
  58. Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009 Jun. 67(6):1167-73. [View Abstract]
  59. Martí-Carvajal AJ, Solà I, Agreda-Pérez LH. Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database Syst Rev. 2014 Jul 10. 7:CD004344. [View Abstract]
  60. Roposch A, Stöhr KK, Dobson M. The effect of the femoral head ossific nucleus in the treatment of developmental dysplasia of the hip. A meta-analysis. J Bone Joint Surg Am. 2009 Apr. 91(4):911-8. [View Abstract]
  61. Piuzzi NS, Chahla J, Schrock JB, LaPrade RF, Pascual-Garrido C, Mont MA, et al. Evidence for the Use of Cell-Based Therapy for the Treatment of Osteonecrosis of the Femoral Head: A Systematic Review of the Literature. J Arthroplasty. 2017 May. 32 (5):1698-1708. [View Abstract]

Avascular necrosis in the femoral head resulting from corticosteroid therapy.

Avascular necrosis of the shoulder showing subchondral radiolucent lines (crescent sign).

Avascular necrosis of both femoral heads. This T1-weighted image shows decreased signal intensity in both femoral heads.

MRI of the distal femur and proximal tibia. This T2-weighted image shows increased signal intensity in the marrow.

Avascular necrosis in the femoral head resulting from corticosteroid therapy.

Avascular necrosis of the shoulder showing subchondral radiolucent lines (crescent sign).

Avascular necrosis of both femoral heads. This T1-weighted image shows decreased signal intensity in both femoral heads.

MRI of the distal femur and proximal tibia. This T2-weighted image shows increased signal intensity in the marrow.

Stage Clinical and Laboratory Findings
Stage 0
  • Patient is asymptomatic.
  • Radiography findings are normal.
  • Histology findings demonstrate osteonecrosis.
Stage I
  • Patient may or may not be symptomatic.
  • Radiography and CT scan findings are unremarkable.
  • AVN is considered likely based on MRI and bone scan results (may be subclassified by extent of involvement [see below]).
  • Histology findings are abnormal.
Stage II
  • Patient is symptomatic.
  • Plain radiography findings are abnormal and include osteopenia, osteosclerosis, or cysts.
  • Subchondral radiolucency is absent.
  • MRI findings are diagnostic.
Stage III
  • Patient is symptomatic.
  • Radiographic findings include subchondral lucency (crescent sign) and subchondral collapse.
  • Shape of the femoral head is generally preserved on radiographs and CT scans.
  • Subclassification depends on the extent of crescent, as follows:
    • Stage IIIa: Crescent is less than 15% of the articular surface.
    • Stage IIIb: Crescent is 15-30% of the articular surface.
    • Stage IIIc: Crescent is more than 30% of the articular surface.
     
     
Stage IV
  • Flattening or collapse of femoral head is present.
  • Joint space may be irregular.
  • CT scanning is more sensitive than radiography.
  • Subclassification depends on the extent of collapsed surface, as follows:
    • Stage IVa: Less than 15% of surface is collapsed.
    • Stage IVb: Approximately 15-30% of surface is collapsed.
    • Stage IVc: More than 30% of surface is collapsed.
     
     
Stage V
  • Radiography findings include narrowing of the joint space, osteoarthritis with sclerosis of acetabulum, and marginal osteophytes.
Stage VI
  • Findings include extensive destruction of the femoral head and joint.